Jayk Bernal News Today : Breaking News, Live Updates & Top Stories | Vimarsana

As the COVID-19 pandemic claimed lives across the globe, several randomised clinical trials were conducted to evaluate the safety and efficacy of investigational and repurposed therapeutics for the treatment of COVID-19. As a result, a number of new antivirals are now licensed to treat COVID-19, such as nirmatrelvir–ritonavir (Paxlovid), molnupiravir, and remdesivir.1–3 Favipiravir is an RNA-dependant RNA polymerase inhibitor with activity against a range of RNA viruses. The agent is licensed in Japan to treat influenza virus and has been studied and subsequently used to treat SARS-CoV-2 i...

As of May, 2022, the SARS-CoV-2 virus has caused 521 million COVID-19 cases and at least 6 million deaths, worldwide.1 Although the COVID-19 pandemic has led to breathtaking vaccine developments, early treatments to prevent progression of COVID-19, especially in those who are most vulnerable, are urgently needed. But to deploy such treatment will take a substantial change in the perception and management of upper respiratory infections, including COVID-19.

For nonhospitalized, unvaccinated adults with mild-to-moderate COVID-19 and at least one risk factor for severe disease, molnupiravir reduced the risk of hospitalization or death.

For nonhospitalized, unvaccinated adults with mild-to-moderate COVID-19, molnupiravir reduces the risk for hospitalization or death.

Efficacy waned during the MOVe-OUT trial